Bullying 'normal occurrence' at Newcastle NHS trust, say CQC
Newcastle Hospitals NHS Foundation Trust’s CQC rating is downgraded to “requires improvement”.
Similar Posts
Ohio boy’s rare and fatal disease, prostate cancer myths, and psychelics for PTSD
Grayson Naff, 8, pictured at right and with his family, was diagnosed with Batten disease in spring 2023. “I really don’t have words for it,” said mom Emily Blackburn to Fox News Digital. (Emily Blackburn) ‘GUT-WRENCHING’ – Emily Blackburn is pushing for research and funds to help her 8-year-old son, Grayson Naff, who has a…
Mental Health in the Age of Social Media: Staying Connected Without Losing Yourself
In just over a decade, social media has transformed how we communicate, work, and even view ourselves. Platforms like Instagram, TikTok, Twitter, and Facebook have become digital gathering spaces for billions of people. While these apps can offer support, inspiration, and a sense of community, they also come with a downside that many people are…
UK Covid inquiry ups sticks to Scotland… in 90 seconds
The UK Covid inquiry has upped sticks from London to Edinburgh. Over the next three weeks, the inquiry will hear evidence from government ministers and experts about decisions taken in Scotland during the pandemic. BBC political correspondent Kirsten Campbell outlines what can be expected during the inquiry’s time north of the border. Video by Morgan…
Covid inquiry: What is it investigating and how does it work?
The second round of public hearings examined how ministers made decisions during the pandemic.
Growing skincare use by children is dangerous, say dermatologists
Dermatologists say products with ingredients potentially harmful to children are growing popular.
Big pharma Merck, Bristol Myers, J&J prepare to lose revenue
The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSE Big pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a…